Oscar Health (NYSE:OSCR) Sets New 1-Year High at $18.69

Oscar Health, Inc. (NYSE:OSCR - Get Free Report) shares hit a new 52-week high during trading on Friday . The stock traded as high as $18.69 and last traded at $18.12, with a volume of 509291 shares traded. The stock had previously closed at $18.09.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. The Goldman Sachs Group lifted their target price on shares of Oscar Health from $8.00 to $16.00 and gave the stock a "neutral" rating in a research note on Friday, February 9th. Wells Fargo & Company raised their price target on Oscar Health from $12.00 to $20.00 and gave the stock an "overweight" rating in a research report on Thursday, February 15th. TheStreet upgraded Oscar Health from a "d" rating to a "c-" rating in a research note on Wednesday, February 21st. Finally, Raymond James began coverage on Oscar Health in a report on Friday, March 22nd. They set an "outperform" rating and a $20.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $13.50.

Oscar Health Stock Down 0.4 %

The business's fifty day moving average price is $15.27 and its 200 day moving average price is $11.58. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $4.14 billion, a PE ratio of -15.30 and a beta of 1.66.

Oscar Health (NYSE:OSCR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 7th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08. The firm had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.43 billion. Oscar Health had a negative return on equity of 29.99% and a negative net margin of 4.62%. The company's revenue for the quarter was up 43.9% on a year-over-year basis. During the same period last year, the company earned ($1.05) earnings per share. On average, equities research analysts forecast that Oscar Health, Inc. will post -0.23 earnings per share for the current fiscal year.

Institutional Trading of Oscar Health

A number of institutional investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its holdings in Oscar Health by 19.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,125,355 shares of the company's stock valued at $6,268,000 after purchasing an additional 182,206 shares during the last quarter. Graham Capital Management L.P. acquired a new position in Oscar Health during the third quarter worth about $894,000. Versor Investments LP purchased a new stake in shares of Oscar Health in the third quarter valued at about $553,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Oscar Health by 270.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 265,031 shares of the company's stock valued at $2,425,000 after purchasing an additional 193,512 shares during the last quarter. Finally, Dark Forest Capital Management LP purchased a new position in shares of Oscar Health during the 3rd quarter worth approximately $581,000. Hedge funds and other institutional investors own 75.70% of the company's stock.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.